Practical Implementation of Universal Hepatitis B Virus Screening for Patients With Cancer.

[1]  Noele P. Nelson,et al.  Cost-Effectiveness of One-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  S. Ramsey,et al.  Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices , 2019, JAMA oncology.

[3]  B. McMahon,et al.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.

[4]  S. Seo,et al.  Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  N. Terrault,et al.  AASLD guidelines for treatment of chronic hepatitis B , 2016, Hepatology.

[6]  M. Brasseur,et al.  Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors , 2015, BMC Cancer.

[7]  K. Kimura,et al.  Outcomes of the implementation of the computer-assisted HBView system for the prevention of hepatitis B virus reactivation in chemotherapy patients: a retrospective analysis , 2015, Journal of Pharmaceutical Health Care and Sciences.

[8]  Kelvin K. W. Chan,et al.  Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis , 2015, Breast Cancer Research and Treatment.

[9]  P. Hsu,et al.  The Compliance of Doctors with Viral Hepatitis B Screening and Antiviral Prophylaxis in Cancer Patients Receiving Cytotoxic Chemotherapy Using a Hospital-Based Screening Reminder System , 2015, PloS one.

[10]  Cynthia Vinson,et al.  Implementation science in cancer prevention and control: a decade of grant funding by the National Cancer Institute and future directions , 2015, Implementation Science.

[11]  J. Crespo,et al.  Computerized physician order entry‐based system to prevent HBV reactivation in patients treated with biologic agents: The PRESCRIB project , 2014, Hepatology.

[12]  G. Schwarzer,et al.  Seroprevalence of Chronic Hepatitis B Virus Infection and Prior Immunity in Immigrants and Refugees: A Systematic Review and Meta-Analysis , 2012, PloS one.

[13]  K. Kowdley,et al.  Prevalence of chronic hepatitis B among foreign‐born persons living in the United States by country of origin , 2012, Hepatology.

[14]  Sanjeev Arora,et al.  Partnering urban academic medical centers and rural primary care clinicians to provide complex chronic disease care. , 2011, Health affairs.

[15]  G. Ioannou.  Hepatitis B Virus in the United States: Infection, Exposure, and Immunity Rates in a Nationally Representative Survey , 2011, Annals of Internal Medicine.

[16]  Sanjeev Arora,et al.  Expanding access to hepatitis C virus treatment—Extension for Community Healthcare Outcomes (ECHO) project: Disruptive innovation in specialty care , 2010, Hepatology.

[17]  J. Hoofnagle,et al.  Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy , 2008, Annals of Internal Medicine.